Armata Pharmaceuticals Inc (ARMP)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$3.00-4.46%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ARMP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
ARMP — CFO transition
Dated 2026-07-20
Chief Financial Officer — David House: David House was promoted to Chief Financial Officer.
Why it matters: Armata named the second half of 2026 as the study start window. Starting on time would mark a key step toward testing its lead drug in a pivotal trial.
Supportive ifBy December 31, 2026, Armata reports that the AP-SA02 Phase 3 study has started. It has enrolled its first patient.
Worry ifArmata reports that the study has not opened by December 31, 2026, or moves the start beyond 2026.
Why it matters: The new $3.7 million award is the first DoW funding for Phase 3 work. More support could help pay for the study without issuing shares.
Supportive ifArmata reports another DoW award for AP-SA02 Phase 3 work, with a stated dollar amount and use of funds.
Worry ifNo added DoW award is reported, or Armata says its current funds cannot cover planned Phase 3 work.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$447 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $1,146 loss on $10,000 · 11.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,122 loss on $10,000 · 81.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.